Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: Two case reports

Journal of Endodontics

Volumn 31, Issue 10, 2005, Pages 759-763

  Sarathy, Aaron P ^a   Bourgeois Jr , Sidney L ^a   Goodell, Gary G ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b NNMC ^*  (United States)

Author keywords

Alendronate; Bisphosphonates; Endodontics; Jaws; Osteonecrosis; Pamidronate; Zoledronate

Indexed keywords

EID: 26844545023     PISSN: 00992399     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.don.0000182737.09980.2c     Document Type: Article

References (19)

1. Melo MD, Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 2005;71:111-3.
2. Robinson NA, Yeo JF. Commentary. Bisphosphonates - a word of caution. Ann Acad Med Singapore 2004;33(Suppl):48S-49S.
3. Lipton A, Coleman RE, Diel IJ, Mundy G. Update on the role of bisphosphonates in metastatic breast cancer. Semin Oncol 2001;28(Suppl 11):2-91.
4. Lindsay R, Cosman F. Osteoporosis. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 2001:2226-37.
5. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
6. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002;8:1080-4.
7. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone. Cancer 2005;104:83-93.
8. Ruggiero SL, Mebrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
9. Marx RE. Letters to the editor. Pamidronate (Aredia) and zoledronate (Zometa) induced vascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
10. Bagan JV, Murillo J, Jimenez J, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.
11. Estilo CL, Williams T, Evtimovska E, et al. Osteonecrosis of the maxilla and mandible: possible drug-induced complication of bisphosphonate therapy [abstract]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;97:449
12. Woo SB, Handle K, Richardson PG. Letter to the editor. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:100
13. Maerevoet M, Martin C, Duck L. Letter to the editor. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:100-1.
14. Durie BGM, Katz M, Crowley J. Letter to the editor. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005;353:99-100.
15. Migliorati CA. Letter to the editor. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:135
16. Sanna G, Zampino MG, Pelosi G, Nole F, Goldhirsch A. Letter to the editor. Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncology 2005;16:1207-13.
17. FDA Patient Safety News: Show #34, December 2004. Caution on osteonecrosis with bisphosphonates. Available: http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/psn/printer.cfm?id=276. Accessed: July 24, 2005.
18. Novartis Pharmaceuticals Corporation. Important drug precaution for dental health professionals with patients being treated for cancer [letter to dentists]. Rockville, MD: US Food and Drug Administration; May 5, 2005. Available: http://www.fda.gov/medwatch/safety/2005/zometa_deardentite_5-5-05. pdf. Accessed: July 24, 2005.
19. Greenberg MS. Editorial. Intravenous bisphosphonates and osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:259-60.